Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1/2 1

Status

Active not recruiting 2

Sponsor Class

OTHER 1INDUSTRY 1

Study Type

Interventional 2

Sponsor

Cancer Type

CNS 2

Conditions

Breast Neoplasms 28HER2-positive Breast Cancer 4Neoplasms 3Multiple Myeloma 3Triple Negative Breast Neoplasms 2Prostatic Neoplasms 2Neoplasm Metastasis 2Lymphoma, Non-Hodgkin 2Endometrial Neoplasms 2Colonic Neoplasms 2Brain Neoplasms 2Anatomic Stage II Breast Cancer AJCC v8 2Anatomic Stage I Breast Cancer AJCC v8 2Uterine Neoplasms 1Uterine Cervical Neoplasms 1Urinary Bladder Neoplasms 1Thyroid Neoplasms 1Stomach Neoplasms 1Solid Tumors 1Salivary Gland Neoplasms 1Resectable HER2-positive Breast Cancer 1Rectal Neoplasms 1Pathologic Complete Response 1Pancreatic Neoplasms 1Ovarian Neoplasms 1Meningeal Neoplasms 1Meningeal Carcinomatosis 1Melanoma 1Malignant Solid Neoplasm 1Lymphoma 1

Interventions

Radiosurgery 23Temozolomide 14Magnetic Resonance Spectroscopy 14pembrolizumab 11Bevacizumab 11Nivolumab 10Ipilimumab 8Specimen Handling 6Memantine 6abemaciclib 5Radiotherapy 5Mental Status and Dementia Tests 5Blood Specimen Collection 5Radiation 4entrectinib 3Surveys and Questionnaires 3Sodium Chloride 3Saline Solution 3Receptors, Interleukin-8B 3Proton Therapy 3Lomustine 3trastuzumab deruxtecan 2trametinib 2pertuzumab 2osimertinib 2lenvatinib 2fluciclovine F-18 2contrast agent BR1 2atezolizumab 2Watchful Waiting 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Brain Neoplasms × pertuzumab × 90 days × Clear all
NCT05593094 2026-05-26

A Phase 1 Trial of ZN-A-1041 Enteric Capsules or Combination in Participants With Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Advanced Solid Tumors

Hoffmann-La Roche

Phase 1/2 Active not recruiting
210 enrolled
CNS

Brain Neoplasms

NCT05323955 2026-03-17

BRIDGET

Duke University

Phase 2 Active not recruiting
48 enrolled
CNS

Brain Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡